## **Product** Data Sheet

## HDAC-IN-44

 Cat. No.:
 HY-150500 

 CAS No.:
 2414921-46-1 

 Molecular Formula:
  $C_{26}H_{27}BrN_4O_4$ 

Molecular Weight: 539.42
Target: HDAC

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

**Description** HDAC-IN-44 is a HDAC inhibitor with the IC<sub>50</sub> value of 61.2 nM.

HDAC-IN-44 shows high anticancer activity towards multiple cancer cell lines<sup>[1]</sup>.

In Vitro HDAC-IN-44 (20 μg/mL; 24 h) treatment shows inhibitory effects on acute lymphoblastic leukemia (Molt 4 cells), T-cell

lymphoblastic lymphoma (Sup-T1 cells), chronic myelogenous leukemia (K562 cells), gastric adenocarcinoma (AGS), prostate cancer (PC3 and LNCaP cells) and breast cancer (T47D cells) [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Molt 4, Sup-T1, K562, AGS, PC-3, LNCaP, T47D cells <sup>[1]</sup>
Concentration:	20 μg/mL
Incubation Time:	24 hours
Result:	Exhibited IC $_{50}$ values of 11, 9.1, 16.3, 7.1, 13.4, 32.7 and 9.2 $\mu$ M in Molt 4, Sup-T1, K562, AGS, PC-3, LNCaP, T47D cells, respectively [1].

## **REFERENCES**

[1]. Ahmed K ElHady et al. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. Bioorg Chem. 2020 May;98:103742.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA